Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

This was the stock's fifth consecutive day of losses.

Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 182 % for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Bristol Myers Squibb (BMY) announced on Friday that its drug, evaluated for myelofibrosis-associated anemia, did not meet its ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Inflation Shock (2022) BMY stock declined 40.2% from a high of $81.13 on 2 December 2022 to $48.48 on 21 November 2023, compared to a peak-to-trough drop of 25.4% for the S&P 500 ...

Bristol-Myers Squibb Company ( NYSE: BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open.

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...